DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by raised blood eosinophils (EOS) and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment1
The following criteria need to be met by your severe asthma patients:1
These severe asthma patients require treatment that will address their Type 2 patient profile
Illustrative patient profiles. Not actual patients.
EOS, eosinophils; FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; IL, interleukin.